The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published today in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology. Read more here.
Study mentioned: Wolchok JD, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013 Jun 2. [Epub ahead of print] PMID: 23724867
No comments:
Post a Comment